Published in PLoS One on August 30, 2011
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One (2012) 1.16
The intersection between DNA damage response and cell death pathways. Exp Oncol (2012) 1.06
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol (2013) 1.03
HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res (2012) 0.95
Autophagy in DNA damage response. Int J Mol Sci (2015) 0.93
Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther (2013) 0.90
DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma. Oncotarget (2015) 0.86
A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res (2016) 0.81
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecol Oncol (2014) 0.81
Genome stability pathways in head and neck cancers. Int J Genomics (2013) 0.79
Shiga toxin 1, as DNA repair inhibitor, synergistically potentiates the activity of the anticancer drug, mafosfamide, on raji cells. Toxins (Basel) (2013) 0.79
Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition. Cancer Res (2012) 0.78
Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Sci Rep (2016) 0.78
Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors. Oncoimmunology (2015) 0.78
Cetuximab induces eme1-mediated DNA repair: a novel mechanism for cetuximab resistance. Neoplasia (2014) 0.77
Selective tumor killing based on specific DNA-damage response deficiencies. Cancer Biol Ther (2012) 0.76
Radiation oncology in vitro: trends to improve radiotherapy through molecular targets. Biomed Res Int (2014) 0.76
Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition. BMC Cancer (2015) 0.75
Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther (2017) 0.75
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Cell death: critical control points. Cell (2004) 22.56
The DNA-damage response in human biology and disease. Nature (2009) 17.86
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol (2003) 6.49
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 5.75
Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res (2002) 4.97
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 4.14
Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev (2002) 3.83
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol (2006) 3.35
Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res (1997) 3.18
Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem (2005) 3.02
Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res (2000) 2.56
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res (2007) 2.52
Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck (2010) 2.51
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res (2005) 2.31
Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res (2006) 1.88
A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer (1972) 1.86
Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol (1997) 1.61
Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol (2007) 1.58
Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther (2009) 1.55
Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm (1999) 1.49
Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem (1998) 1.48
Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A (2010) 1.47
Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck (2002) 1.32
Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys (2007) 1.31
Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res (2008) 1.30
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res (2010) 1.29
Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res (2010) 1.22
DNA damage induces p53-dependent BRCA1 nuclear export. J Biol Chem (2004) 1.18
Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol (2000) 1.15
Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in mice. J Clin Invest (2009) 1.13
Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654. FEBS Lett (2010) 1.10
A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer Res (2009) 1.08
Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6∗I. Int J Radiat Oncol Biol Phys (2010) 1.00
DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Cancer Res (2010) 0.98
An in vivo model for squamous cell carcinoma of the head and neck. Laryngoscope (1985) 0.97
EGFR inhibitor C225 increases the radiosensitivity of human lung squamous cancer cells. Cancer Cell Int (2010) 0.82
AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs (2010) 0.82
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Comparison of plan quality and delivery time between volumetric arc therapy (RapidArc) and Gamma Knife radiosurgery for multiple cranial metastases. Neurosurgery (2014) 3.38
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol (2010) 2.71
Patterns of surgical care of lung cancer patients. Ann Thorac Surg (2005) 2.51
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol (2003) 2.32
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol (2007) 1.87
Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.81
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol (2007) 1.66
Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol (2010) 1.63
Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2008) 1.56
Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2002) 1.55
Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2009) 1.34
Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res (2008) 1.30
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys (2002) 1.28
Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys (2008) 1.27
The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol (2011) 1.18
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther (2007) 1.18
Prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer: a comprehensive review and call for evidence-based medicine. JPEN J Parenter Enteral Nutr (2011) 1.16
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One (2012) 1.16
Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol (2007) 1.13
Postoperative radiotherapy in non-small-cell lung cancer warrants further exploration in the era of adjuvant chemotherapy and conformal radiotherapy. J Clin Oncol (2006) 1.13
Smoking behavior of 226 patients with diagnosis of stage IIIA/IIIB non-small cell lung cancer. Psychooncology (2002) 1.11
Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resist Updat (2007) 1.10
Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. Oncogene (2004) 1.09
p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res (2011) 1.03
Comparison of manual and automatic segmentation methods for brain structures in the presence of space-occupying lesions: a multi-expert study. Phys Med Biol (2011) 1.02
Design and development of water-soluble curcumin conjugates as potential anticancer agents. J Med Chem (2007) 1.01
Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer (2005) 1.01
DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Cancer Res (2010) 0.98
RapidArc radiation therapy: first year experience at the University of Alabama at Birmingham. Int J Radiat Oncol Biol Phys (2010) 0.96
HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res (2012) 0.95
Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiother Oncol (2011) 0.95
TRAIL receptor-targeted therapy. Future Oncol (2006) 0.95
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma (2012) 0.95
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs (2006) 0.95
Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res (2004) 0.94
MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. Clin Cancer Res (2012) 0.93
Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res (2012) 0.92
Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer (2005) 0.92
Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy. J Appl Clin Med Phys (2013) 0.92
Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer (2011) 0.92
The role of mTOR inhibition in augmenting radiation induced autophagy. Technol Cancer Res Treat (2007) 0.92
PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis? Cancers (Basel) (2013) 0.92
Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. Front Mol Neurosci (2011) 0.91
Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem (2003) 0.90
Gastrostomy tube placement and use in patients with head and neck cancer. Head Neck (2011) 0.90
Margin on gross tumor volume and risk of local recurrence in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 0.90
Kinomic profiling approach identifies Trk as a novel radiation modulator. Radiother Oncol (2012) 0.89
Validation of target volume and position in respiratory gated CT planning and treatment. Med Phys (2003) 0.89
More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med (2007) 0.88
Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis. Mayo Clin Proc (2004) 0.88
Reduction of dose delivered to organs at risk in prostate cancer patients via image-guided radiation therapy. Int J Radiat Oncol Biol Phys (2009) 0.87
Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J Surg Res (2003) 0.86
History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol (2003) 0.86
Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther (2005) 0.86
Effect of niclosamide on basal-like breast cancers. Mol Cancer Ther (2014) 0.85
Comparison of methods to reduce dose to swallowing-related structures in head and neck cancer. Int J Radiat Oncol Biol Phys (2009) 0.85
Epigenetic inactivation of DNA repair in breast cancer. Cancer Lett (2012) 0.85
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiat Oncol (2014) 0.84
Optimal planning target volume margins for elective pelvic lymphatic radiotherapy in high-risk prostate cancer patients. ISRN Oncol (2013) 0.84
Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J Med Chem (2010) 0.83
Model prediction of treatment planning for dose-fractionated radioimmunotherapy. Cancer (2002) 0.83
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers. Breast Cancer Res Treat (2015) 0.83
Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies. Radiat Oncol (2012) 0.83
A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. Qual Life Res (2002) 0.82
Intraoperative radiotherapy for head and neck and skull base cancer. Head Neck (2003) 0.82
Diagnosis-to-treatment interval and control of locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg (2011) 0.81
Effects of flattening filter-free and volumetric-modulated arc therapy delivery on treatment efficiency. J Appl Clin Med Phys (2013) 0.81
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leuk Lymphoma (2007) 0.81
Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers. J Gastrointest Cancer (2009) 0.81
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. J Nucl Med (2009) 0.80
Hypofractionated Prostate Radiotherapy with or without Conventionally Fractionated Nodal Irradiation: Clinical Toxicity Observations and Retrospective Daily Dosimetry. Prostate Cancer (2012) 0.80
Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute. Radiat Oncol (2013) 0.80
Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer. Head Neck (2010) 0.80
Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy. Radiat Oncol (2014) 0.80
Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Bioconjug Chem (2004) 0.79
Examination of laryngoesophageal dysfunction-free survival as an endpoint in nonsurgical treatment of squamous cell carcinomas of the larynx and hypopharynx. Cancer (2011) 0.79
Discussion of PARP inhibitors in cancer therapy. Pharm Pat Anal (2013) 0.79
Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients. J Gastroenterol (2009) 0.79
Assaying DNA damage in hippocampal neurons using the comet assay. J Vis Exp (2012) 0.78
Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. Anticancer Drugs (2014) 0.78
Patterns of prophylactic gastrostomy tube placement in head and neck cancer patients: a consideration of the significance of social support and practice variation. Laryngoscope (2013) 0.77
Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer. Head Neck (2012) 0.77
Segmentation editing improves efficiency while reducing inter-expert variation and maintaining accuracy for normal brain tissues in the presence of space-occupying lesions. Phys Med Biol (2013) 0.77
A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734. Clin Lung Cancer (2007) 0.77
A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1). Int J Radiat Oncol Biol Phys (2002) 0.76
Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol (2016) 0.75
Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation. Radiother Oncol (2011) 0.75
Correction: Kinomic Profiling of Electromagnetic Navigational Bronchoscopy Specimens: A New Approach for Personalized Medicine. PLoS One (2016) 0.75